Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia

Haematologica

Volumn 100, Issue 5, 2015, Pages e169-e171

  Origa, Raffaella ^a   Cazzola, Mario ^b   Mereu, Elisabetta ^a   Danjou, Fabrice ^a   Barella, Susanna ^c   Giagu, Nicolina ^c   Galanello, Renzo ^a   Swinkels, Dorine W ^d  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Osp Regionale per le Microcitemie   (Italy)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Erythropoiesis hepcidin iron store axis; Hemoglobin H disease; thalassemia intermedia

Indexed keywords

DEFEROXAMINE; ERYTHROPOIETIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR; IRON;

ADULT; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; FEMALE; GASTRULATION; GENE MUTATION; GLOBIN GENE; HEMOGLOBIN H DISEASE; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; IRON CHELATION; IRON STORAGE; LETTER; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; THALASSEMIA INTERMEDIA; UPREGULATION; ALPHA-THALASSEMIA; BETA-THALASSEMIA; BLOOD; IRON OVERLOAD; METABOLISM;

ALPHA-THALASSEMIA; BETA-THALASSEMIA; ERYTHROPOIESIS; GROWTH DIFFERENTIATION FACTOR 15; HEMOLYSIS; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD;

EID: 84928493089     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115733     Document Type: Letter

References (15)

1. Cazzola M, Barosi G, Bergamaschi G, et al. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol. 1983;54(4):649-654.
2. Cazzola M, Beguin Y, Bergamaschi G, et al. Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. Br J Haematol. 1999;106(3):752-755.
3. Finch C. Regulators of iron balance in humans. Blood. 1994;84(6):1697-1702.
4. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109(11):5027-5035.
5. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-588.
6. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-1101.
7. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin in murine and human cells. Blood. 2009;114(1):181-186.
8. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
9. Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Hematology Am Soc Hematol Educ Program. 2009:26-34.
10. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010;56(10):1570-1579.
11. Rees DC, Williams TN, Maitland K, Clegg JB, Weatherall DJ. Alpha thalassemia is associated with increased soluble transferrin receptor levels. Br J Haematol. 1998;103:365-369.
12. Papassotiriou I, Traeger-Synodinos J, Kanavakis E, Karagiorga M, Stamoulakatou A, Kattamis C. Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease. J Pediatr Hematol Oncol. 1998;20(6):539-544.
13. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117(25):e218-225.
14. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011; 57(12):1650-1669.
15. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood. 2005;105(10):4103-4105.